Outcome summary
Variable . | Total . | Skin only . | Systemic only without skin . | Skin and systemic . | Incomplete staging . | P* . |
---|---|---|---|---|---|---|
N, total | 54 | 11 | 10 | 27 | 6 | |
OS 1 y % (95% CI) | 70 (55-81) | 90 (47-98) | 60 (25-83) | 64 (42-79) | 100 | .17 |
2 y % (95% CI) | 49 (34-62) | 80 (41-95) | 30 (7-58) | 43 (23-61) | 50 (1-91) | |
Initiated treatment, N | 44 | 10 | 8 | 25 | 1 | |
PFS 1 y % (95% CI) | 55 (39-68) | 80 (41-95) | 38 (9-67) | 52 (31-69) | 0 | .36 |
2 y % (95% CI) | 34 (21-48) | 60 (25-83) | 13 (1-42) | 32 (15-50) | 0 | |
Transplanted, N† | 25 | 5 | 5 | 15 | 0 | |
OS 1 y % (95% CI) | 80 (58-91) | 80 (20-97) | 80 (20-97) | 80 (50-93) | — | .69 |
2 y % (95% CI) | 60 (38-76) | 80 (20-97) | 40 (5-75) | 60 (32-80) | — | |
N, allogeneic transplant | 20 | 2 | 5 | 13 | ||
Cumulative incidence 1 y aGVHD grade 2-4, % (95% CI) | 42 (20-63) | 100 | 60 (7-91) | 31 (9-57) | — | .36 |
aGVHD grade 2-4 | 9 (45) | 2 (100) | 3 (60) | 4 (31) | — | — |
Skin | 2 | 1 | 0 | 1 | ||
Skin and liver | 1 | 1 | 0 | 0 | ||
Skin and lower GI | 1 | 0 | 0 | 1 | ||
Skin and upper GI | 2 | 0 | 1 | 1 | ||
Upper GI | 2 | 0 | 2 | 0 | ||
Lower and upper GI | 1 | 0 | 0 | 1 | ||
Cumulative incidence 1 y cGVHD, % (95% CI) | 20 (6-40) | 0 | 20 (4-63) | 23 (5-49) | — | .79 |
cGVHD | 4 (20) | 0 (0) | 1 (20) | 3 (23) | — | — |
Muscle and myositis | 1 | 0 | 0 | 1 | ||
Liver and lower GI | 1 | 0 | 0 | 1 | ||
Lung | 1 | 0 | 0 | 1 | ||
Kidneys | 1 | 0 | 1 | 0 |
Variable . | Total . | Skin only . | Systemic only without skin . | Skin and systemic . | Incomplete staging . | P* . |
---|---|---|---|---|---|---|
N, total | 54 | 11 | 10 | 27 | 6 | |
OS 1 y % (95% CI) | 70 (55-81) | 90 (47-98) | 60 (25-83) | 64 (42-79) | 100 | .17 |
2 y % (95% CI) | 49 (34-62) | 80 (41-95) | 30 (7-58) | 43 (23-61) | 50 (1-91) | |
Initiated treatment, N | 44 | 10 | 8 | 25 | 1 | |
PFS 1 y % (95% CI) | 55 (39-68) | 80 (41-95) | 38 (9-67) | 52 (31-69) | 0 | .36 |
2 y % (95% CI) | 34 (21-48) | 60 (25-83) | 13 (1-42) | 32 (15-50) | 0 | |
Transplanted, N† | 25 | 5 | 5 | 15 | 0 | |
OS 1 y % (95% CI) | 80 (58-91) | 80 (20-97) | 80 (20-97) | 80 (50-93) | — | .69 |
2 y % (95% CI) | 60 (38-76) | 80 (20-97) | 40 (5-75) | 60 (32-80) | — | |
N, allogeneic transplant | 20 | 2 | 5 | 13 | ||
Cumulative incidence 1 y aGVHD grade 2-4, % (95% CI) | 42 (20-63) | 100 | 60 (7-91) | 31 (9-57) | — | .36 |
aGVHD grade 2-4 | 9 (45) | 2 (100) | 3 (60) | 4 (31) | — | — |
Skin | 2 | 1 | 0 | 1 | ||
Skin and liver | 1 | 1 | 0 | 0 | ||
Skin and lower GI | 1 | 0 | 0 | 1 | ||
Skin and upper GI | 2 | 0 | 1 | 1 | ||
Upper GI | 2 | 0 | 2 | 0 | ||
Lower and upper GI | 1 | 0 | 0 | 1 | ||
Cumulative incidence 1 y cGVHD, % (95% CI) | 20 (6-40) | 0 | 20 (4-63) | 23 (5-49) | — | .79 |
cGVHD | 4 (20) | 0 (0) | 1 (20) | 3 (23) | — | — |
Muscle and myositis | 1 | 0 | 0 | 1 | ||
Liver and lower GI | 1 | 0 | 0 | 1 | ||
Lung | 1 | 0 | 0 | 1 | ||
Kidneys | 1 | 0 | 1 | 0 |